Clinical trials: Primary Liver Cancer
Advanced Primary Liver Cancer
Clinical Trial of Elemene in Combination With Oxaliplatinin the Treatment of Advanced Primary Liver Cancer
Clinical Trial of Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin in the First -line treatment of advanced primary liver cancer
- Trial name
- NCT03166553
- Testing
- Elemene
- Where
- 10 sites in China
- Volunteers
- 150 people
- Sponsor
- BeiJing Yijiayi Medicine Techonoloy Co., Ltd.
Primary Hepatocellular Carcinoma
Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 injection.This study will be conducted in combination with camrelizumab in patients with advanced advanced primary hepatocellular carcinoma who have received at least one…
- Trial name
- NCT06124001
- Testing
- Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), camrelizumab for Injection
- Volunteers
- 36 people
- Sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.
Fallopian Tube Cancer, Metastatic Cancer
ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ILX-295501 in treating patients who have stage III or…
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005645
- Testing
- ILX-295501
- Where
- 8 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Liver Cancer
Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer
This is a prospective, multicenter, randomized, parallel-controlled, non-inferiority clinical trial that will be conducted at multiple clinical trial institutions in China.
- Trial name
- NCT07356531
- Testing
- Transcatheter Arterial Chemoembolization
- Where
- 15 sites in China
- Volunteers
- 216 people
- Sponsor
- JIANGSU SHENMING Medical Technology CO., Ltd
Liver Cancer (Primary and Metastatic)
Short-term Embolization Using Gelatin Particles for FloW ModulAtion During Y90 Radioembolization
The SEGWAY trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of flow diversion to protect non-tumorous liver function using short-acting gelatin sponge particles during Yttrium-90…
- Trial name
- SEGWAY (NCT06229080)
- Testing
- NexGel
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Next Biomedical Co., Ltd.
Liver Cancer
Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective for liver cancer.
- Trial name
- NCT00012324
- Testing
- doxorubicin hydrochloride, nolatrexed dihydrochloride
- Where
- 42 sites in United States, Canada and 1 more
- Sponsor
- Eximias Pharmaceutical
Primary Liver Cancer
Polyvinyl Alcohol Embolization Microspheres
To evaluate the safety and efficacy of polyvinyl alcohol embolization microspheres developed and manufactured by Shanghai Huihe Medical Technology Co., LTD.
- Trial name
- NCT05770635
- Testing
- Embosphere and chemotherapy drug, Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Shanghai Huihe Medical Technology Co., Ltd
Cancer of the Liver
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
To evaluate objective response rate and duration of response to weekly Taxoprexin®. To evaluate the safety profile of weekly Taxoprexin® in this patient population. To evaluate overall survival in the same patient population.
- Trial name
- NCT00422877
- Testing
- Taxoprexin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- American Regent, Inc.
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Hepatocellular Carcinoma
To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer
Through the implementation of prospective, multi-center, single-group target value research to verify the safety and effectiveness of the microwave ablation treatment system for the ablation treatment of primary liver cancer.
- Trial name
- NCT04520906
- Testing
- microwave ablation
- Where
- 13 sites in China
- Volunteers
- 61 people
- Sponsor
- Suzhou Hengruihongyuan Medical Technology Co. LTD
Carcinoma, Hepatocellular
Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC)
The purpose of this study is to evaluate the safety and efficacy of the NanoKnife LEDC System for the treatment of early-stage hepatocellular carcinoma (HCC).
- Trial name
- NCT01078415
- Testing
- Ablation with the NanoKnife Low Energy Direct Current (LEDC) System
- Where
- 6 sites in France, Germany and 2 more
- Volunteers
- 26 people
- Sponsor
- Angiodynamics, Inc.
Liver Cancer
Safety of 32P BioSilicon in Patients With Hepatocellular Carcinoma
Brachytherapy is a recent technique used in the treatment of tumours and involves the use of radioactive sources brought into close contact with the target tissues.
- Trial name
- NCT00247260
- Testing
- 32P BioSilicon
- Where
- Singapore
- Volunteers
- 50 people
- Sponsor
- pSiVida Limited
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Primary Liver Cancer
Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers
GNS561 is a drug used in preliminary phase 1b study for treatment of patients with primary and secondary liver cancer. The formulation used was oral capsule.The objective of this study in healthy volunteers is to compare…
- Trial name
- NCT05353894
- Testing
- GNS561 oral tablets and capsules
- Where
- France
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Genoscience Pharma
Hepatocellular Carcinoma
Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003
The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced primary hepatocellular carcinoma The primary endpoint is best overall response rate within 20 weeks after registration
- Trial name
- NCT00405873
- Testing
- AMT2003
- Where
- 2 sites in Germany
- Volunteers
- 73 people
- Sponsor
- Auron Healthcare GmbH
Hepatocellular Carcinoma (HCC)
Computer Guided Microwave Liver Ablation
The goal of this clinical trial is to learn if the intraoperative use of a computer guidance software can improve the success of liver tumor ablation in adults.
- Trial name
- MWA Sim (NCT07226869)
- Testing
- Computer-Assisted Microwave Liver Ablation
- Where
- 2 sites in United States
- Volunteers
- 84 people
- Sponsor
- NE Scientific INC
Neoplasms, Liver
A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma
The primary purpose of this study is to determine the maximum tolerable dose (MTD) and/or the maximum feasible dose (MFD), as well as to evaluate the safety of JX-594 (Pexa-Vec) injected within hepatic carcinoma tumors.
- Trial name
- NCT00629759
- Testing
- JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
- Where
- South Korea
- Volunteers
- 14 people
- Sponsor
- Jennerex Biotherapeutics
Primary Liver Cancer
Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This phase I study will be conducted in HSV-seropositive subjects with advanced primary liver cancer that are refractory to conventional therapies.
- Trial name
- NCT04806464
- Testing
- Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
- Where
- China
- Volunteers
- 44 people
- Sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.
Neoplasm Metastasis
Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden
The purpose of this study is to determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.
- Trial name
- OXi4503 (NCT00960557)
- Testing
- Combretastatin A1 Diphosphate (OXi4503)
- Where
- 4 sites in Australia
- Volunteers
- 16 people
- Sponsor
- Mateon Therapeutics